| Therapy for treating malignancies |
2023-5-08 |
2023-9-07 |
|
| Pyruvate kinase activators for use in treating blood disorders |
2023-5-03 |
2023-5-18 |
|
| Mitapivat, or a pharmaceutically acceptable salt thereof, in particular … |
2023-5-02 |
2023-7-26 |
|
| Compounds and methods useful for stabilizing phenylalanine hydroxylase … |
2023-2-27 |
2023-8-31 |
|
| (4-benzo[d]oxazol-2-yl)-6,7-dihydro-1h-imidazo[4,5-c]pyridine-5(4h)-yl) … |
2023-2-27 |
2023-8-31 |
|
| Compounds and methods useful for stabilizing phenylalanine hydroxylase … |
2023-2-27 |
2023-8-31 |
|
| Methods of treating brain tumors using combination therapy |
2022-12-15 |
2023-2-21 |
|
| Methods of treating brain tumors using combination therapy |
2022-12-12 |
2023-2-14 |
|
| Methods of treatment of acute myeloid leukemia characterized by the presence of … |
2022-11-29 |
2023-1-01 |
|
| Compounds for treating mds-associated anemias and other conditions |
2022-11-15 |
2023-5-25 |
|
| Bcat2 inhibitors |
2022-11-11 |
2023-6-22 |
|
| Therapeutically active compounds and their methods of use |
2022-11-01 |
2023-1-24 |
|
| Tablet compositions |
2022-9-22 |
2022-12-27 |
|
| Methods for titrating mitapivat |
2022-4-28 |
2023-3-01 |
|
| Methods for titrating mitapivat |
2022-2-08 |
2023-8-17 |
|
| Crystalline forms of n-(4-(4-(cyclopropylmethyl)piperazine-1-carbonyl)phenyl) … |
2022-1-14 |
2022-7-14 |
|
| Methods of using pyruvate kinase activators |
2021-12-15 |
2022-7-07 |
|
| Crystalline salt forms of n-(4-(4-(cyclopropylmethyl)piperazine-1-carbonyl) … |
2021-11-16 |
2022-1-01 |
|
| Pharmaceutical preparation |
2021-9-24 |
2023-8-08 |
|
| PHARMACEUTICAL FORMULATION |
2021-9-24 |
2022-12-21 |
|
| Pharmaceutical formulation |
2021-9-24 |
2023-8-02 |
|
| Automated identification of potential drug safety events |
2021-9-17 |
2022-1-06 |
|
| Thieno[3,2-b]pyrrole[3,2-d]pyridazinone derivatives and use thereof as pkm2 … |
2021-9-10 |
2021-12-10 |
|
| Pharmaceutical compositions of therapeutically active compounds |
2021-9-07 |
2021-12-16 |
|
| Therapeutically active compound and its method of use |
2021-7-29 |
2021-11-11 |
|
| THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF PREPARATION |
2021-7-07 |
2022-10-12 |
|
| Therapeutically active compounds and their methods of use |
2021-5-25 |
2021-8-26 |
|
| Combination therapy for treating malignancies |
2021-5-25 |
2021-9-09 |
|
| Methods for titrating mitapivat for use in treating thalassemia |
2021-4-30 |
2022-11-03 |
|
| Combination therapy for treating malignancies |
2021-4-16 |
2021-8-12 |
|
| Menin inhibitors and methods of use for treating cancer |
2021-4-07 |
2021-10-14 |
|
| Menin inhibitors and methods of use for treating cancer |
2021-4-07 |
2022-2-01 |
|
| Pyruvate kinase activators for use in therapy |
2021-4-02 |
2021-7-22 |
|
| Small molecule menin inhibitors |
2021-3-31 |
2021-5-31 |
|
| Idh1 inhibitors for treatment of hematological malignancies and solid tumors |
2021-3-18 |
2021-7-15 |
|
| Therapy for treating malignancies |
2021-3-16 |
2021-7-08 |
|
| Mat2a inhibitors for treating mtap null cancer |
2021-3-10 |
2021-7-01 |
|
| Pharmaceutical compositions of therapeutically active compounds |
2021-3-05 |
2021-6-10 |
|
| Methods of treating autoimmune or inflammatory diseases or disorders |
2021-2-04 |
2021-8-12 |
|
| Inhibitor of cell metabolism process |
2021-2-01 |
2021-5-13 |
|
| Methods of preparing 6-(aryl or heteroaryl)-1,3,5-triazine-2,4-diols and 6-( … |
2021-1-27 |
2021-3-11 |
|
| Ivosidenib forms and pharmaceutical compositions |
2021-1-04 |
2021-9-13 |
|
| Deuterated analogs of an idh1 inhibitor |
2020-11-20 |
2021-5-27 |
|
| Piperidine compounds as menin inhibitors |
2020-9-29 |
2021-7-16 |
|
| Heterobicyclic inhibitors of mat2a and methods of use for treating cancer |
2020-9-29 |
2023-6-01 |
|
| Treatment of tumors incorporating mutant isocitrate dehydrogenase |
2020-9-01 |
2021-3-25 |
|
| A method for preparing ivosidenib and an intermediate thereof |
2020-8-07 |
2021-6-01 |
|
| Therapeutically active compounds and their methods of use |
2020-6-18 |
2022-11-03 |
|
| Methods of treatment with aminolevulinic acid synthase 2 (alas2) modulators |
2020-6-05 |
2021-2-25 |
|
| HETEROBICYCLIC MAT2A INHIBITORS AND THEIR USE FOR THE TREATMENT OF VARIOUS … |
2020-5-29 |
2021-11-17 |
|
| Combination therapy for treating malignancies |
2020-5-21 |
2021-4-08 |
|
| Therapeutically active compounds and their methods of use |
2020-5-13 |
2020-9-17 |
|
| Therapeutically active compounds and their methods of use |
2020-5-11 |
2020-10-29 |
|
| Cocrystals, pharmaceutical compositions thereof, and methods of treatment … |
2020-4-22 |
2021-3-22 |
|
| Combination therapy for treating malignancies |
2020-4-13 |
2020-12-31 |
|
| Methods and compositions for cell-proliferation-related disorders |
2020-2-14 |
2020-9-10 |
|
| Combination therapies for use in treating cancer |
2020-2-13 |
2020-12-16 |
|
| Heterobicyclic inhibitors of mat2a and methods of use for treating cancer |
2019-12-27 |
2020-11-01 |
|
| Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer |
2019-12-27 |
2020-7-02 |
|
| Crystalline and salt forms of an organic compound and pharmaceutical … |
2019-12-20 |
2020-8-06 |
|
| Compounds and their methods of use |
2019-10-08 |
2020-2-06 |
|
| CELLULAR METABOLIC PROCESS INHIBITORS |
2019-3-13 |
2019-5-31 |
|
| Inhibitors of cellular metabolic processes |
2019-2-21 |
2019-10-21 |
|
| Method of using trisubstituted benzotriazole derivatives |
2019-2-19 |
2020-10-28 |
|
| Therapeutically active compounds and their use |
2019-1-09 |
2019-6-27 |
|
| Methods of using deuterated pyruvate kinase activators |
2018-11-15 |
2019-5-23 |
|
| Therapeutically active compounds and their methods of use |
2018-11-15 |
2019-5-23 |
|
| Therapeutically active compounds and their methods of use |
2018-10-23 |
2019-4-25 |
|
| Compounds and their methods of use |
2018-10-10 |
2018-12-14 |
|
| PIPERAZINE DERIVATIVES AS PYRUVATE KINASE M2 (PKM2) MODULATORS |
2018-9-13 |
2019-12-11 |
|
| Pyruvate kinase activators for use in the treatment of blood disorders |
2018-8-15 |
2021-11-30 |
|
| PYRUVATE KINASE MODULATORS AND THE USE OF THEM |
2018-8-15 |
2019-10-30 |
|
| Therapeutic compound and composition |
2018-7-10 |
2018-12-20 |
|
| Glutaminase inhibitors and methods of use |
2018-6-28 |
2018-7-19 |
|
| Method for treating cell proliferation related disorders |
2018-4-26 |
2019-9-12 |
|
| Therapeutically active compounds and their methods of use |
2017-10-12 |
2018-2-08 |
|
| INHIBITORS OF CELLULAR METABOLIC PROCESSES |
2017-8-31 |
2018-12-12 |
|
| Inhibitors of cellular metabolic processes |
2017-8-30 |
2021-5-27 |
|
| Bicyclic PKM2 Activators |
2017-7-10 |
2017-12-28 |
|
| N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as idh2 … |
2017-6-22 |
2017-12-07 |
|
| Compounds, their pharmaceutical compositions and their uses as idh1 mutants … |
2017-6-13 |
2017-10-05 |
|
| Therapeutic compositions and related methods of use |
2017-4-14 |
2017-10-05 |
|
| Therapeutic compound and composition |
2017-3-07 |
2017-6-15 |
|
| Use of e-cadherin and vimentin for selection of treatment responsive patients |
2017-2-28 |
2017-10-19 |
|
| Therapeutically active compounds and their methods of use |
2017-1-24 |
2021-5-26 |
|
| Therapeutically active compositions and their methods of use |
2016-12-26 |
2017-3-23 |
|
| Therapeutically active compositions and their methods of use |
2016-12-13 |
2017-6-15 |
|
| Therapeutically active compounds and their methods of use |
2016-10-20 |
2017-8-11 |
|
| 2,4- or 4,6-diaminopyrimidine compounds as idh2 mutants inhibitors for the … |
2016-10-20 |
2017-8-11 |
|
| Combination therapy for treating malignancies |
2016-10-14 |
2022-3-15 |
|